HeyJaredBecky McCall
- Indexed articles, last 90 days
- 9
- Latest publication
- Oct 1, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Aug 28, 2026
Latest articles
EloraTZP Boosts Weight Loss, A1c Reduction in T2D (opens the original)
Read excerpt
MILAN — Combining the investigational amylin receptor agonist, eloralintide, with tirzepatide produced greater weight loss than either drug alone in adults with overweight/obesity and type 2 diabetes (T2D), results of a phase 2 trial showed. Participants receiving the highest-dose combination (eloralintide 9 mg plus tirzepatide 15 mg), lost an average of 23.3% of their body weight, compared with 14.8% among those receiving tirzepatide 15 mg alone and 11.1% in those receiving eloralintide 9 mg al
SURPASS-CVOT Looks Beyond the Heart: Tirzepatide Signals Benefits in Infection Mortality, Patient-Reported Outcomes (opens the original)
Read excerpt
MILAN —New analyses from the SURPASS-CVOT trial suggest that differences between tirzepatide and dulaglutide in people with type 2 diabetes (T2D) and established cardiovascular disease (CVD) may extend beyond traditional cardiovascular outcomes, with signals emerging in favor of tirzepatide for lower noncardiovascular mortality and improvements in patient-reported health and daily functioning. The findings prompted discussion here at the European Association for the Study of Diabetes (EASD) 2026
HRT Plus Exercise Improves Insulin Sensitivity (opens the original)
Read excerpt
MILAN —Combining hormone replacement therapy (HRT) with exercise produced the largest observed improvement in insulin sensitivity among postmenopausal women compared to exercise or HRT alone, interim results from a 12-week randomized study showed. Exercise, both with and without HRT, also substantially improved physical strength and increased peak aerobic capacity. HRT plus exercise produced a slightly greater reduction in fat mass than exercise alone, with both exercise groups showing significa
Tricuspid Repair Cuts Death, HF Hospitalization in Severe TR (opens the original)
Read excerpt
MUNICH — Transcatheter tricuspid valve repair added to medical therapy substantially reduced the risk for death or heart failure (HF) hospitalization compared with medical therapy alone in high-risk patients with severe tricuspid regurgitation (TR), according to results from the randomized Tricuspid Intervention in HF (TRIC-I-HF) trial. At 3 years, tricuspid repair plus medical therapy was associated with a 60% lower risk for death or HF hospitalization than medical therapy alone. “Tricuspid rep
Faster 1-Hour MI Rule-Out Is Safe (opens the original)
Read excerpt
MUNICH — Switching from a 3-hour to a 1-hour high-sensitivity cardiac troponin pathway for patients with suspected myocardial infarction (MI) was safe, but unexpectedly, did not shorten emergency department (ED) stays in a large, pragmatic, real-world trial. Despite delivering the second troponin result about 2 hours earlier, the accelerated pathway left median ED length of stay unchanged at 309 minutes, suggesting that simply making diagnostic information available sooner may not be enough to i
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.